Company
Headquarters: Taipei, Taiwan
CEO: Dr. Yue-Teh Jang
TW$12.62 Billion
TWD as of July 1, 2025
US$431.1 Million
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $193.76 B |
| EssilorLuxottica SA | $128.90 B |
| Becton, Dickinson and Company | $50.81 B |
| Alcon Inc. | $44.33 B |
| HOYA Corp | $40.30 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Medeon Biodesign, Inc. develops and markets medical device solutions in Taiwan. It focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. The company was founded in 2012 and is headquartered in Taipei, Taiwan.
Medeon Biodesign, Inc. has the following listings and related stock indices.
Stock: TWSE: 6499 wb_incandescent